About PTC Therapeutics Inc.

PTC Therapeutics Inc., founded in 1998, has established itself as a leader in developing therapies for rare genetic diseases through its scientific platform focused on RNA biology and post-transcriptional control mechanisms. The company has successfully brought multiple products to market for ultra-rare diseases while building a diverse pipeline of novel therapies. PTCT stock price reflects the company's commercial success with approved products and continued pipeline advancement in high-value rare disease markets.

Led by CEO Matthew Klein, MD, who brings extensive biopharmaceutical industry experience, PTC Therapeutics has built an integrated rare disease company with capabilities spanning discovery through commercialization. The management team combines scientific expertise with commercial execution capabilities, having successfully launched products globally while maintaining a productive research engine. Leadership's strategic focus on sustainable growth through both internal development and strategic partnerships has been crucial for creating shareholder value and supporting PTCT stock price performance.

PTC Therapeutics operates as a fully integrated biopharmaceutical company with commercial products generating revenue while investing in pipeline expansion. The company's marketed products treat Duchenne muscular dystrophy and phenylketonuria, with additional programs in development for various genetic disorders. With established commercial infrastructure, multiple revenue-generating products, and a robust pipeline targeting rare diseases where successful therapies command premium pricing, PTCT offers investors a differentiated biotechnology investment with both current revenue generation and significant growth potential from pipeline advancement.